Research Analysts Offer Predictions for CRVS FY2028 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at HC Wainwright reduced their FY2028 earnings estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst S. Lee now forecasts that the company will earn $0.11 per share for the year, down from their prior estimate of $0.14. HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' FY2029 earnings at $0.44 EPS.

Separately, Oppenheimer reissued an "outperform" rating and issued a $15.00 price objective (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

Corvus Pharmaceuticals Price Performance

NASDAQ:CRVS traded down $0.22 during trading hours on Thursday, reaching $3.17. 452,858 shares of the stock were exchanged, compared to its average volume of 592,959. The stock has a market cap of $203.37 million, a PE ratio of -3.40 and a beta of 0.91. Corvus Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $10.00. The firm has a 50 day moving average of $4.61 and a 200 day moving average of $6.07.

Remove Ads

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06).

Institutional Investors Weigh In On Corvus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Corvus Pharmaceuticals by 22.4% during the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company's stock worth $2,974,000 after buying an additional 102,869 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth about $265,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Corvus Pharmaceuticals by 64.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company's stock valued at $724,000 after purchasing an additional 53,809 shares during the period. State Street Corp lifted its stake in Corvus Pharmaceuticals by 48.2% in the 3rd quarter. State Street Corp now owns 178,246 shares of the company's stock valued at $941,000 after purchasing an additional 57,943 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Corvus Pharmaceuticals during the third quarter worth about $74,000. Institutional investors own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.